BIOCHEMICAL SOCIETY TRANSACTIONS
479-492 and 1 : 100 against GABA, receptor purified from adult bovine'cerebral cortex. The titre is defined as that dilution of serum which would produce an absorbance equal to half of the maximum response. The immune response against purified GABA, receptor, measured by ELISA was blocked by preincubating the serum with the free Cys-a3 479-492 peptide (Fig. la) .
A Western blot of purified GABA, from adult bovine cerebral cortex is shown in Fig. 1( b) . Antisera raised against Cys-a3 479-492 reacted with a polypeptide with M , 59 000-60 000. This is in contrast with the antiserum raised against the a 1 isoform-specific peptide, a 1 1-1 5, which reacted predominantly with a polypeptide of M , 5 3 000.
Both a 1 and a 3 immunoreactivity were found in GABA, receptor preparations purified from adult bovine cerebral cortex, cerebellum, hippocampus and 12-day-old calf cerebral cortex (Stephenson et al. (1989) ).
Thus, we have demonstrated the presence of a polypeptide which was predicted from the identification of a cDNA which encodes the a3 subunit. This polypeptide has M , 59 000-60 000 compared with a molecular mass of 52 000 Da calculated from the deduced primary structure; the difference is attributed to N-glycosylation (Levitan et al., 1988) . The a 3 subunit was not found previously because in one-dimensional SDS/PAGE it comigrates with the Psubunit ( M , 57 000-58 000). Kirkness & Turner (1988) have recently shown that the P-band can be resolved using antibodies which can be predicted to recognize all three asubunit isoforms.
In several species, photoaffinity labelling of the GABA, receptor with the benzodiazepine, [ 3H]flunitrazepam has shown that bands other than the a-subunit incorporated radiolabel (reviewed in Stephenson, 1988) . The discovery of isoforms of the a-subunit with different M , may explain these results. The isoform-specific antibodies described here may serve as important tools in the elucidation of their functional importance. ( 1 986) We have previously described a monoclonal antibody, mab SM gp65, which recognizes two immunologically related, central nervous system-specific glycoproteins of mean apparent M, values of 65 000 (gp65) and 55 000 (gpSS), Hill er al. (1987a Hill er al. ( , h, 1988 . Gp6S is only present on subsets of fore-and mid-brain ncurones where it is expressed along the neuronal processes, extending into the nerve terminals. Gp65 is enriched in isolated post-synaptic densities (psds), whereas gpSS is absent from this fraction. GpSS is expressed in cultures of cerebellar granule cells and cerebral cortex neurones, but not astrocytes. More recent studies show that the two glycoproteins may only differ substantially by a single peptide fragment, M, 12 000. (Willmott et al., 1989) .
Gp65 and gp5.5 levels in tissue samples were determined by quantitative Western blotting. The blots were developed with mab SM gp65 followed by '251-labelled anti-mouse Ig F( ab), fragments. Quantification was achieved either by densitometric scanning o f autoradiograms or by direct counting of the radiolabelled glycoprotein bands as Abbreviations used: E, embryonic day; mab, monoclonal antibody; P, post-natal day; psd, post-synaptic density. +To whom correspondence should be addressed.
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described by Hill et al. (1988) . Psds were prepared from animals of known post-natal age by the method of Curd et ul. (1982) . Cerebellar granule cell and cerebral cortex neurones were cultured as described by Atterwill et al. (1984) and Choi et al. ( 1987) , respectively.
The results show striking differences in the developmental profiles of gpSS and gp6S. In forebrain samples (Fig. la) , gpS5 is detectable as early as embryonic day (E) 14 and a rapid increase in level is observed from birth to post-natal day ( P ) 12. The level then plateaus to 80% of adult, a further 20% increase being observed between P30 and the adult animal (P84-108). In contrast to gpS5, gp6S is not detectable prenatally and by P12 it has only attained 13% of the adult level. Thereafter, its level increases rapidly so that by P24, 9.5% of the adult level has been attained. Thus while the developmental profile for gp6S is similar in shape to that for gpSS, it occurs some 2 weeks later.
Gp5S development in cerebellum (Fig. l b ) differs markedly from that observed for forebrain. While the glycoprotein is still expressed prenatally, its levels continue to rise over a much longer period than in forebrain. The shape of the profile is consistent with two phases of gpSS expression. The first occurs from E l 4 to P12, 46% of the peak gpS.5 level having been attained by this time. The remaining 54% increase occurs between P12 and P21. Thereafter, there is a modest (go/") decrease in gpSS level. The level of gp65 is low throughout cerebellar development, though it may be expressed somewhat earlier than in forebrain.
Analysis of forebrain psds prepared from P12-P28 rats shows that the psd gp65 content exactly parallels the increase in the level of the glycoprotein observed in whole forebrain homogenate. Only trace levels of gpS.5 are observed in psds prepared from animals at any developmental stage.
The two tissue culture systems examined differ markedly in their expression of gp65/gp5.5. Cerebellar granule cells show good expression of gp.5.5 and its level continues to increase throughout the culture period (12 days in vitro). In contrast, gp6.5 is only ever poorly expressed in these cultures. Thus the pattern of development in these cultures closely resembles that observed in cerebellum in vivo. Cultures of forebrain cortical neurones express both gp65 and gp.55. The levels of both glycoproteins increase during the first 6 days in vitro. Thereafter, the levels begin to fall, but this is concomitant with neuronal degeneration. Gp6.5 expression is therefore occurring in these cultures much earlier than would be observed in vivo.
It is now important to study the molecular mechanisms which account for the different patterns of expression of these two glycoproteins.
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